文献速递肿瘤 PET/CT核素与放射性配体治疗

合理设计的核靶向FAPI 04基分子探针增强肿瘤摄取用于PET/CT和荧光成像

A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-21

本研究将亚甲蓝(MB)偶联至FAPI构建NOTA-FAPI-MB探针,赋予其核靶向和荧光成像能力,并在FAP转染细胞、人原代癌症相关成纤维细胞、荷瘤小鼠及肝细胞癌患者组织中进行评估。NOTA-FAPI-MB对FAP转染细胞和CAFs的靶向能力优于NOTA-FAPI;荷瘤小鼠PET/CT中[18F]F-NOTA-FAPI-MB的肿瘤摄取标准化摄取值(2.20±0.31)高于[18F]F-FDG(1.66±0.14);荧光成像肿瘤阳性率NOTA-FAPI-MB为100.0%(6/6),ICG为33.3%(2/6)。

要点

  • NOTA-FAPI-MB对FAP转染细胞和CAFs的靶向能力优于NOTA-FAPI,归因于阳离子MB对阴离子核酸的亲和力。
  • 荷瘤小鼠PET/CT中[18F]F-NOTA-FAPI-MB肿瘤摄取SUV为2.20±0.31,高于[18F]F-FDG的1.66±0.14。
  • 荧光成像肿瘤阳性率NOTA-FAPI-MB为100.0%(6/6),ICG为33.3%(2/6)。

核心结论

  • NOTA-FAPI-MB成功合成,FAPI和MB共同贡献靶向作用;探针的核递送机制提高了细胞内滞留时间和靶向效力,拓宽了荧光成像时间窗口。
  • 体内PET/CT显示NOTA-FAPI-MB相比[18F]F-FDG表现良好;本研究强调荧光成像作为PET/CT辅助技术的意义。
  • 人肝细胞癌组织成像的鼓舞性结果提示NOTA-FAPI-MB在临床术中荧光手术引导中具有潜在应用前景。

研究设计与样本

  • 本研究设计并合成NOTA-FAPI-MB探针,在FAP转染细胞系和人原代癌症相关成纤维细胞(CAFs)上评估靶向效力。
  • 在荷瘤小鼠上进行PET/CT和荧光成像。
  • 对肝细胞癌(HCC)患者组织进行荧光成像以评估肿瘤检测和边界勾画。

主要发现

  • NOTA-FAPI-MB对FAP转染细胞和CAFs的靶向能力优于NOTA-FAPI,该优势源于阳离子亚甲蓝(MB)对阴离子核酸的亲和力。
  • 荷瘤小鼠PET/CT显示[18F]F-NOTA-FAPI-MB的肿瘤摄取标准化摄取值(SUV)为2.20±0.31,高于[18F]F-FDG的1.66±0.14。
  • 体内荧光成像显示肿瘤部位滞留时间延长,滞留持续长达24小时。
  • 荧光探针较临床使用的吲哚菁绿(ICG)实现更精确的病灶检测和肿瘤边缘勾画,NOTA-FAPI-MB肿瘤阳性率为100.0%(6/6),ICG为33.3%(2/6)。

关键数值与推荐

  • NOTA-FAPI-MB肿瘤阳性率为100.0%(6/6),ICG为33.3%(2/6)。
  • [18F]F-NOTA-FAPI-MB肿瘤摄取SUV为2.20±0.31,[18F]F-FDG为1.66±0.14。
  • 体内荧光成像肿瘤部位滞留持续长达24小时。

临床怎么用

  • 作者认为NOTA-FAPI-MB在术中荧光手术引导中具有潜在应用前景。
  • 本研究强调荧光成像作为PET/CT辅助技术的意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fibroblast activation protein inhibitor (FAPI) -based probes have been widely studied in the diagnosis of various malignant tumors with positron emission tomography/computed tomography (PET/CT). However, current imaging studies of FAPI-based probes face challenges in rapid clearance rate and potential false-negative results. Furthermore, FAPI has been rarely explored in optical imaging. Considering this, further modifications are imperative to improve the properties of FAPI-based probes to address existing limitations and broaden their application scenarios. In this study, we rationally introduced methylene blue (MB) to FAPIs, thereby imparting nuclei-targeting and fluorescence imaging capabilities to the probes. Furthermore, we evaluated the added value of FAPI-based fluorescence imaging to traditional PET/CT, exploring the potential application of FAPI-based probes in intraoperative fluorescence imaging. METHODS: A new FAPI-based probe, namely NOTA-FAPI-MB, was designed for both PET/CT and fluorescence imaging by conjugation of MB. The targeting efficacy of the probe was evaluated on fibroblast activation protein (FAP)-transfected cell line and human primary cancer-associated fibroblasts (CAFs). Subsequently, PET/CT and fluorescence imaging were conducted on tumor-bearing mice. The tumor detection and boundary delineation were assessed by fluorescence imaging of tissues from hepatocellular carcinoma (HCC) patients. RESULTS: NOTA-FAPI-MB demonstrated exceptional targeting ability towards FAP-transfected cells and CAFs in comparison to NOTA-FAPI. This benefit arises from the cationic methylene blue (MB) affinity for anionic nucleic acids. PET/CT imaging of tumor-bearing mice revealed significantly higher tumor uptake of [18F]F-NOTA-FAPI-MB (standard uptake value of 2.20 ± 0.31) compared to [18F]F-FDG (standard uptake value of 1.66 ± 0.14). In vivo fluorescence imaging indicated prolonged retention at the tumor site, with retention lasting up to 24 h. In addition, the fluorescent probes enabled more precise lesion detection and tumor margin delineation than clinically used indocyanine green (ICG), achieving a 100.0% (6/6) tumor-positive rate for NOTA-FAPI-MB while 33.3% (2/6) for ICG. These findings highlighted the potential of NOTA-FAPI-MB in guiding intraoperative surgical procedures. CONCLUSIONS: The NOTA-FAPI-MB was successfully synthesized, in which FAPI and MB simultaneously contributed to the targeting effect. Notably, the nuclear delivery mechanism of the probes improved intracellular retention time and targeting efficacy, broadening the imaging time window for fluorescence imaging. In vivo PET/CT demonstrated favorable performance of NOTA-FAPI-MB compared to [18F]F-FDG. This study highlights the significance of fluorescence imaging as an adjunct technique to PET/CT. Furthermore, the encouraging results obtained from the imaging of human HCC tissues hold promise for the potential application of NOTA-FAPI-MB in intraoperative fluorescent surgery guidance within clinical settings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhao X, Zhang G, Chen J, et al. A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging. Eur J Nucl Med Mol Imaging. 2024. PMID: 38512485. doi:10.1007/s00259-024-06691-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。